chrisvoncsefalvay/vaers-outcomes huggingface dataset:
RECEIVED LESS THAN 0.5 ML OF VACCINE AS A BOOSTER DOSE (0.3 ML); OFF LABEL USE; This spontaneous report received from a health care professional concerned a 42 year old female. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient was previously received covid-19 vaccine ad26. cov2. s from unspecified manufacturer (form of admin, route of admin, and batch number were not reported), 1 in total, dose was not reported for prophylactic vaccination (Dose number in series 1). The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 213D21A, expiry: 11-APR-2022) with dose less than 0.5 ml (approximately around 0.3ml) 1 total, administered (Dose number in series 2) on 01-DEC-2021 to left arm for prophylactic vaccination which was an off label use as patient received less than 0.5ml of the Janssen covid-19 vaccine as a booster dose (LLT: Vaccine underdose). No concomitant medications were reported.  As per the report, the HCP withdrew 8 doses of the Janssen Covid-19 vaccine from 5 vials and 7 doses from 1 vial which injected into 48 individuals. When the caller had a discussion with that HCP, mentioned that he/she injected 0.5mL but the caller mentioned that the math (she arrived at that by dividing 2.5mL by 5 doses) did prove that they received approximately around 0.3mL.(Dose number in series 2) The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the received less than 0.5 ml of vaccine as a booster dose (0.3 ml) and off label use was not reported. This report was non-serious. This case, from the same reporter is linked to 20211210684, 20211210197, 20211210409, 20211210067, 20211209551, 20211210160, 20211210058, 20211209843, 20211209775, 20211210549, 20211210610, 20211210159, 20211210733, 20211210408, 20211210555, 20211209880, 20211210133, 20211209816, 20211209782, 20211212088, 20211212082, 20211209679, 20211209740, 20211210588, 20211210670, 20211210824, 20211209912, 20211210350, 20211210141, 20211210585 and 20211210107.
pt recv vax & devel inj site rxn characterized by redness, pain, induration, warmth, & swelling the size of a softball or larger;
This spontaneous report as received from a office manager regarding several unspecified patients of unknown age and demographics. The patients concurrent condition and medical history was not provided. On or after 12-FEB-2015 at unspecified times, the patients were vaccinated with improperly stored PEDVAX HIB lot# J016187; expiry date: 21-OCT-2016; lot: K002747; expiry date: 09-FEB-2016 (also reported as 09-DEC-2016) and H021853; expiry date: 11-OCT-2015. No adverse effects reported. This is one of several reports from the same reporter. Additional information has been requested.
After my J&J vaccine, I experienced left hip and joint pain. I could not lift my left leg up. The next morning after my J&J vaccine, my left leg started hurting more and I could not ambulate. My left hip was hurting so bad I could not sleep at night. I went to the doctor 03-17-2021 to get monitored and he said it could be arthritis. I was prescribed by Dr.  cyclobenzaprine 10mg and naproxen 500mg. I feel that my pain is inside the joint, hip pain region and to this day, I still have sleeping problems due to my pain in my left leg and left hip pain since the J&J vaccine. I will have a  follow up with Dr. in the coming weeks.
Pt called health system call center to report that she had received Moderna #1 on 4/27/2021 from outside facility - Vaccination site at 2400 (Lot 043B21A).   On 4/29/2021, the following symptoms presented: intermitted cough, SOB (improved slightly with coughing), drowsiness and fatigue. Denies fevers. Pt was advised to go to ED if symptoms worsen.  Pt was scheduled for urgent care visit on 5/4/21 during which pt was prescribed APAP as needed. COVID nasal swab on 5/4/21 was negative.
Patient reported pain and numbness in arm night of vaccination. reported going to the ER was discharged same night
After my shot, I had low fever and was  tired and reported those on the daily checker. On 4/16 my right side lymph node on neck/ear/face started swelling and on Saturday it  was very swollen and also noticed swollen lump at injection site on right arm, and both still there today...Sunday
Within 10min pt returned to office w/cough, wheezing and SOB. Pt also had facial swelling. Benadryl and Duo Neb given in office.
Patient was seen in our office on 1/10/2017 complained of severe left shoulder pain (rating 8 out of 10) with "certain movements," states started after she received the flu vaccine one month ago. Pt stated that the day after she received the shot, she had the normal soreness associated with the vaccine but the next day, there was pain that has not gone away with no redness or swelling present. Denies injury. Denies fever. Denies pain to any other joints. Denies left shoulder pain at this time. Left shoulder X-rays was ordered for patient.
Headache; swelling on the injection site; injection site warmth; injection site redness; injection site itching; slight fever; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 12-May-2021 and was forwarded to Moderna on 12-May-2021.    This spontaneous case was reported by a patient and describes the occurrence of PYREXIA (slight fever), HEADACHE (Headache), SWELLING (swelling on the injection site), INJECTION SITE WARMTH (injection site warmth) and INJECTION SITE ERYTHEMA (injection site redness) in a 60-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 023C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concomitant products included RAMIPRIL (TENAPRIL) for an unknown indication.   On 08-May-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-Apr-2021, the patient experienced PYREXIA (slight fever). On 09-May-2021, the patient experienced HEADACHE (Headache), SWELLING (swelling on the injection site), INJECTION SITE WARMTH (injection site warmth), INJECTION SITE ERYTHEMA (injection site redness) and INJECTION SITE PRURITUS (injection site itching). At the time of the report, PYREXIA (slight fever), HEADACHE (Headache), SWELLING (swelling on the injection site), INJECTION SITE WARMTH (injection site warmth), INJECTION SITE ERYTHEMA (injection site redness) and INJECTION SITE PRURITUS (injection site itching) outcome was unknown.            No treatment medication were not reported   This case was linked to MOD-2021-119054 (Patient Link).   Reporter did not allow further contact
Pt recvd vax 15AUG91 & on 17AUG devel rash, taken to ER & stated rash from vax, temp elevated but did not take it; On 26AUG pt was taken to MD, devel hives on top of rash; MD ordered DPH & Calmine lotion; also exp sl cough, runny nose;
No additional AE reported; A patient was administered VARIVAX two days after the administration of MMR II; This spontaneous report was received from a nurse concerning a patient of unknown age and gender. Information regarding the patient's medical history, concurrent conditions and concomitant medications was not reported.       On 20-JUL-2021, the patient was vaccinated with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) for prophylaxis (strength, dose, frequency, route of administration, anatomical location, lot number and expiration date were not provided).      On 22-JUL-2021, the patient was vaccinated varicella virus vaccine live (oka/merck) (VARIVAX) (inappropriate schedule of product administration) 0.5 milliliter, for prophylaxis (lot number S032355 had been determined to be valid for varicella virus vaccine live (oka/merck), expiration date reported and established as 14-OCT-2021)  (strength, route of administration and anatomical location were not provided).     No adverse event reported.
This spontaneous report as received from a pharmacist refers to an infant of unknown age and gender. The patients' concurrent conditions and medical history were not reported. On 22-JU-2015, the patient was vaccinated with a dose of improperly stored RECOMBIVAX HB (doses and routes of administration were not reported, lot number K010535, expiration date 27-AUG-2016 or lot number K020216 and expiration date 17-SEP-2016). No adverse effects were reported. This is one of several reports received from the same source. Additional information has been requested.
103 degree Fahrenheit fever for 3 days.  Excessive sweating.  Skin turned red all over entire body and took on the rough texture of a football.  Persistent headache.  Low energy.  Contacted Doctors.  No medicine prescribed.  Plenty of rest, water, and NSAIDs as required.   Four and a half months after second Moderna COVID 19 vaccine recieved, developed what a different doctor described as "the worst case of Shingles" he had ever seen.  That lasted a full month.  Multiple Shingles prescriptions filled.  I still have lasting, painful yet numb nerve damage in my chest, shoulder, and back from the Shingles.
The MMR vaccine had expiration date of 11/14/2018. The MMR was given on 11/27/2018. The MA that gave the vaccine only looked at the month and year of expiration and did not realize the vaccine had expired.
Patient loss consciousness while standing at check-out about 15 minutes after receiving both vaccines. Patient also had labs collected via venipuncture after the vaccines where administered.
DRUG ERUPTION (GENERALIZED ITCHINESS ALL OVER BODY WHICH INTENSIFIED, RASH ALL OVER BODY, LEGS, STOMACH, BACK, AND THEN ALL TORSO); LUMP ON RIGHT ARM (FEEL LIKE A KNOT IN MUSCLE); GOT SCARED; This spontaneous report received from a patient concerned a 68 year old male. The patient's height, and weight were not reported. The patient's past medical history included: several surgeries, and steroid shots, and concurrent conditions included: slightly elevated cholesterol, acid reflux, and blood pressure, and other pre-existing medical conditions included: Patient was taking blood pressure medications and statins. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805018, and expiry: UNKNOWN) dose was not reported, administered on 17-MAR-2021 for prophylactic vaccination. No concomitant medications were reported. On MAR-2021, the patient experienced drug eruption (generalized itchiness all over body which intensified, rash all over body, legs, stomach, back, and then all torso). On MAR-2021, the patient experienced lump on right arm (feel like a knot in muscle). On MAR-2021, the patient experienced got scared. On 22-SEP-2021, Laboratory data included: Diagnostic ultrasound (NR: not provided) not provided. Laboratory data (dates unspecified) included: Lab test (NR: not provided) diagnosis: drug eruption. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient was recovering from lump on right arm (feel like a knot in muscle), had not recovered from drug eruption (generalized itchiness all over body which intensified, rash all over body, legs, stomach, back, and then all torso), and the outcome of got scared was not reported. This report was non-serious.
Expected arthralgia and myalgia for 4 days. Unexpected onset of severe shaking chills awakening from sleep which for persisted for about 1 hour after taking naproxen. Chills did not recur.
Swelling at injection site started within 15 minutes of injection over the next day the site grew to golf ball size with redness and heat very painful. Injection site continues to be golf ball size, hot to touch, and red and purple in the area now day 5.
a patient received two doses of Menveo one week apart - got one on 16Oct2023, and another on 23Oct2023; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a 12-year-old female patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVA985A, expiry date 21-OCT-2024) for prophylaxis.   Concomitant products included MENVEO.   On 23-OCT-2023, the patient received the 2nd dose of Menveo. On 23-OCT-2023, an unknown time after receiving Menveo, the patient experienced drug dose administration interval too short (Verbatim: a patient received two doses of Menveo one week apart - got one on 16Oct2023, and another on 23Oct2023). The outcome of the drug dose administration interval too short was unknown.   Additional Information: GSK receipt date: 23-Oct-2023 The vaccine administration facility was the same as primary reporter. The reporter consented to follow-up, pharmacy mailing address in HCP details. The patient received 2nd dose of Menveo earlier than the recommended interval, which led to shortening of vaccine schedule.
I had a lot of mucus drainage in my sinuses, down my throat, after Thanksgiving, I felt very fatigued. I tried using over the counter medication for cough and allergies. It was not good for my body. I finally went to my doctor who took me off of everything over the counter. He gave me Flonase for my allergies and once my body finally detoxed from the over-the-counter medications, I started to feel much better.
Information has been received from a healthcare worker concerning a 61 year old male patient who on Sept 23 2004 was vaccinated with a dose of pneumococcal 23v polysaccharide vaccine (lot 647029/0460P). On Sept 23 2004 the patient had a swollen arm. On Sept 24 2004 the patient developed a rash all over the body. Unspecified medical attention was sought. No product quality complaint involved. It was reported to be unknown if this was the first or second vaccination. It was also reported that another patient had a similar reaction (WAES0411USA00241). Additional information has been requested.
NO ADVERSE EVENTS REPORTED, PATIENT WAS ADMINISTERED VACCINE THAT EXPIRED BY 2 DAYS
LPN rpt pt recv 1dose varivax 5/9/95 & on 6/21/95 pt devel 5-6 skin lesions
Patient came in for an WC  appointment on 3-17-21 at 2:30 pm . Provider ordered DTAP and  patient was given a TDAP  by MA  by mistake. Mother was notified of vaccine error and educated on signs and symptoms of an allergic reaction. No Adverse events reported from mother.
Tight chest, difficulty breathing, fatigue for 2 weeks, no appetite for 2 weeks, low white blood cell count
allergic to something; terrible headache; nausea; chills; fever; vomiting (5 vomits); R arm hurts a lot; This spontaneous case was reported by a consumer and describes the occurrence of HYPERSENSITIVITY (allergic to something), HEADACHE (terrible headache), NAUSEA (nausea), CHILLS (chills) and PYREXIA (fever) in a 53-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 027CC21A and 037821A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 11-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 09-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 09-May-2021, the patient experienced HEADACHE (terrible headache), NAUSEA (nausea), CHILLS (chills), PYREXIA (fever), VOMITING (vomiting (5 vomits)) and MYALGIA (R arm hurts a lot). On an unknown date, the patient experienced HYPERSENSITIVITY (allergic to something). At the time of the report, HYPERSENSITIVITY (allergic to something), HEADACHE (terrible headache), NAUSEA (nausea), CHILLS (chills), PYREXIA (fever), VOMITING (vomiting (5 vomits)) and MYALGIA (R arm hurts a lot) outcome was unknown. Not Provided          No concomitant medications were reported No treatment drugs were reported
atrial fibrillation as captured by smartphone (i can send PDF if desired)  at 5:44pm ...irregular heartbeat caused me to capture event on my phone, especially since I had a similar reaction to the first shot.
11/7/14 Received flu vaccine in upper left deltoid. Shoulder pain decreased mobility has slowly increased. Unable to raise left arm over shoulder. Unable to step on left side.
Skin rash; This is a spontaneous report from a non-contactable consumer, the patient. A 20-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FC3183) via an unspecified route of administration in the left arm on 10Sep2021 at 16:30 (at the age of 20-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was diagnosed with COVID-19. The concomitant medications were not reported. The patient did not receive any other vaccine within four weeks prior to the COVID-19 vaccine. On 12Sep2021, the patient experienced skin rash. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of skin rash. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event skin rash was not recovered at the time of this report.  No follow-up attempts are possible. No further information is expected.
I had the shot, but later had shingles also/Suspected vaccination failure; Later had shingles also.; This case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine.     Additional Information: GSK Receipt Date: 17th Apr 2022 Reporter's Comments: This case was reported by a consumer via interactive digital media. The case was reported by patient. The patient had shingles vaccine and later got shingles too. Additional Supportive Information: This case was considered as suspected vaccination failure since details regarding completion of primary vaccination schedule, time to onset and laboratory confirmation of shingles not given. The follow up would not be possible since no contact details provided.
This spontaneous report was received from the registered nurse regarding a 19 months old patient of unknown gender. The patient's medical history, concurrent conditions, drug allergies/reactions and concomitant medications were not provided. On 05-DEC-2018, the patient was vaccinated with improperly stored VARIVAX (product storage error) lot # N031001 and expiration date 03-NOV-2019 (doses, frequencies, routes were not provided) for prophylaxis which were reconstituted with a properly stored sterile diluent (unknown manufacturer) lot # M037021 with expiration date 04-MAY-2019. The vaccine was stored at a temperature of -9 degree Celsius to 8 degree Celsius, time frame of 2 hours and 15 minutes. The vaccine was also stored out of range at -6 degree Celsius for an approximate time of 15 minutes. There was no previous temperature excursion. Digital Data logger was involved. The date of VARIVAX storage error was 22-JUL-2018. No adverse events were reported. The outcome of the event product storage error and no adverse event were unknown. This is one of the several report received from same reporter. Sender's Comments: US-009507513-1807USA011693.
At 12:15 pm I stared having brain fog and mild I jections site pain. At 10 pm I have sever body aches , chills , fatigue, injection site pain was sever fever of 100  by 2 am- 5 am I had pain zaps .  I took Tylenol at 12:30 am 6 am ,1 pm and 6 pm
Patient had some pain in her arm that then radiated to her chest. At time of report that pain had been going on for 5 days. Patient was told to visit with her doctor for follow-up.
This case was reported by a nurse via call center representative and described the occurrence of influenza-like symptoms in an unspecified number of female patient who received SHINGRIX (batch number 4492P, expiry date unknown). On an unknown date, the patient received the 1st dose of SHINGRIX .5 ml. On an unknown date, less than a day after receiving SHINGRIX, the patient experienced influenza-like symptoms, chills, sleeplessness and tremor. On an unknown date, the outcome of the influenza-like symptoms, chills, sleeplessness and tremor were recovered/resolved. The reporter considered the influenza-like symptoms, chills, sleeplessness and tremor to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. The reporter stated that the 3 or 4 patients, she believed all to be female received the first dose of SHINGRIX and all were given 0.5ml dose in the left deltoid, and all patients experienced flu like symptoms on the evening of the vaccine. The reporter noted the events resolved after about 2 days. The reporter did not have patient's details. All the patients were back in to the see the nurse, but the physician saw them as well in the office. The reporter did not have patient's details. All the patients were back in to see the see the nurse, but the physician saw them as well in the office. The reporter was transferred to Immunization Information System to address if the second dose should be given. The reporter did not believe any had other vaccines on the same day or 4 weeks prior to. The patients visited emergency room.
pt was given Medquadfi by mistake and then given the correct vaccine of Quadracell
felt a little hot after the first vaccine but did not have a fever; headache; This spontaneous case was reported by a consumer and describes the occurrence of FEELING HOT (felt a little hot after the first vaccine but did not have a fever) and HEADACHE (headache) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 645A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 17-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 17-Mar-2021, the patient experienced FEELING HOT (felt a little hot after the first vaccine but did not have a fever) and HEADACHE (headache). At the time of the report, FEELING HOT (felt a little hot after the first vaccine but did not have a fever) and HEADACHE (headache) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged.       No Concomitant medications were reported. No Treatment mediations were reported.   This case was linked to MOD-2021-404090 (Patient Link).
pt recv vax tilting of head to the left w/extension of lt upper extremity for a few seconds;no jerking & no eyeball movement;
several hr p/inj devel pain & redness @ inj site noted malaise, myalgias, & t100.1;8cm x17cm area of redness w/small red streak proximal to large area of erythema;tenderness w/o induration;Ibuprofen